
Lp(a), an overlooked yet potent cardiovascular risk factor, is up to six times more atherogenic than LDL. It drives plaque inflammation and clot formation, heightening heart disease risks. With genetic determinants, a one-time test can identify high-risk individuals. Promising Lp(a)-lowering therapies, including gene editing and monoclonal antibodies, are under investigation, aiming for better cardiovascular outcomes.
Like
Save
Share